Last reviewed · How we verify
SB-1121(1)
SB-1121(1) is a Small molecule drug developed by Nguyen Thi Trieu, MD. It is currently FDA-approved. Also known as: Cirrhosis/SB-1121.
SB-1121(1) is a composition being studied for the treatment of cirrhosis and liver cancer. The study, NCT05178303, is a completed clinical trial that investigated the efficacy of SB-1121 in treating these conditions.
At a glance
| Generic name | SB-1121(1) |
|---|---|
| Also known as | Cirrhosis/SB-1121 |
| Sponsor | Nguyen Thi Trieu, MD |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SB-1121(1) CI brief — competitive landscape report
- SB-1121(1) updates RSS · CI watch RSS
- Nguyen Thi Trieu, MD portfolio CI
Frequently asked questions about SB-1121(1)
What is SB-1121(1)?
Who makes SB-1121(1)?
Is SB-1121(1) also known as anything else?
What development phase is SB-1121(1) in?
Related
- Manufacturer: Nguyen Thi Trieu, MD — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Cirrhosis/SB-1121
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing